Centessa Pharmaceuticals to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference
Centessa Pharmaceuticals (Nasdaq: CNTA) announced that CEO Saurabh Saha will participate in an analyst-led fireside chat at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 14, 2021, at 5:00 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Centessa Pharmaceuticals (Nasdaq: CNTA) announced that CEO Saurabh Saha will participate in an analyst-led fireside chat at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 14, 2021, at 5:00 p.m. ET. A live audio webcast will be available on the investor relations section of Centessa's website, with a replay accessible for 90 days post-event. Centessa focuses on bringing new medicines to patients through a specialized, asset-centric approach, targeting various therapeutic areas such as oncology and immunology.
Details
News Market Reaction – CNTA
The recorded move for CNTA in the trading session of this news was +4.06%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass. & LONDON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, M.D., Ph.D., Chief Executive Officer, will participate in an analyst-led fireside chat at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on Tuesday, September 14, 2021, beginning at 5:00 p.m. Eastern Time.
A live audio webcast of this event can be accessed on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/events-presentations. Replay of the webcast will be archived on the Company's website for 90 days following the event.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc aims to bring impactful new medicines to patients by combining the strengths of an asset-centric model with the benefits of scale and diversification typical of larger R&D organizations. The asset-centric model refers to a highly specialized, singular-focused company that is led by a team of well-recognized subject matter experts. Centessa’s asset-centric companies’ programs range from discovery-stage to late-stage development and include diverse therapeutic areas such as oncology, hematology, immunology/inflammation, neuroscience, hepatology, pulmonology and nephrology. For more information, visit www.centessa.com.
Contacts:
| Investor Contact: | Media Contacts: |
| Jennifer Porcelli, Head of Investor Relations | US |
| Centessa Pharmaceuticals | Dan Budwick, 1AB |
| jennifer.porcelli@centessa.com | dan@1abmedia.com |
| UK/Greater Europe | |
| Mary Clark & Shabnam Bashir, Optimum Strategic Communications | |
| centessa@optimumcomms.com | |
| Switzerland | |
| Marcus Veith, VEITHing Spirit | |
| marcus@vspirit.ch | |
| M: +41 79 20 75 111 |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.